<DOC>
	<DOCNO>NCT00310011</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , paclitaxel , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine together paclitaxel cisplatin work treat patient advance transitional cell cancer urothelium .</brief_summary>
	<brief_title>Gemcitabine , Paclitaxel , Cisplatin Treating Patients With Advanced Cancer Urothelium</brief_title>
	<detailed_description>OBJECTIVES : - Determine response gemcitabine hydrochloride , paclitaxel , cisplatin ( GTP ) among patient regional distant metastasis transitional cell carcinoma urothelium local/regional recurrence cystoprostatectomy . - Determine response patient receive GTP initial chemotherapeutic treatment well patient receive prior chemotherapy . - Determine response duration , freedom progression , overall survival . - Assess toxicity GTP . OUTLINE : This open-label study . Patients stratify accord prior chemotherapy ( yes v ) . Patients receive paclitaxel IV 3 hour cisplatin IV 1 hour day 1 gemcitabine hydrochloride IV 30 minute day 1 8 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients achieve partial response complete response undergo surgical restaging debulking . Four 6 week later , patient receive 2 additional course chemotherapy . After completion study treatment , patient follow every 3 month 1 year every 6 month thereafter . PROJECTED ACCRUAL : A total 71 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma ( TCC ) urothelium ( bladder , renal pelvis , ureter ) TCC squamous glandular element No pure squamous cell carcinoma adenocarcinoma Disease amenable local curative treatment Regional distant metastasis TCC urothelium OR local/regional recurrence cystectomy , cystoprostatectomy , nephroureterectomy , ureterectomy If regional metastasis present alone , histological confirmation metastasis require No clinically evident brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 0 1 Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL Creatinine ≤ 1.6 mg/mL Bilirubin ≤ 1.8 mg/mL SGOT ≤ 3 time upper limit normal Life expectancy &gt; 3 month No known sensitivity E. coliderived product No prior concurrent malignancy except active/inactive nonmelanoma skin cancer , adequately treated stage I II cancer currently complete remission , observationonly earlystage prostate cancer No serious medical illness would limit survival &lt; 3 month No psychiatric condition would limit compliance study requirement No active uncontrolled bacterial , viral , fungal infection unless correct control No hemorrhagic disorder Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior systemic chemotherapy regimen Prior intravesical therapy allow Prior definitive radiation renal pelvis , ureter , bladder allow No concurrent chemotherapy nonstudy drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
</DOC>